Mitochondrial Renewal
82
síntesis
3
550,000
advanced
May 17, 2026
Visión General
The Mitochondrial Renewal stack targets the organelles responsible for 90% of cellular energy production — mitochondria — whose dysfunction is now recognized as a central driver of aging and age-related disease. SS-31 (Elamipretide, also known as Bendavia) is a cell-penetrating tetrapeptide that concentrates 1000-5000x in the inner mitochondrial membrane, where it binds cardiolipin. Cardiolipin is essential for electron transport chain complex organization, and its oxidation with age leads to respiratory chain inefficiency, ROS overproduction, and energy failure. SS-31 stabilizes cardiolipin, restoring electron transport efficiency and reducing oxidative damage at its source. It has completed Phase 3 trials for Barth syndrome and Phase 2 for heart failure. MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome''s 12S rRNA gene. It acts as a retrograde signal from mitochondria to the nucleus, activating AMPK (the cellular energy sensor) and promoting metabolic homeostasis. MOTS-c enhances glucose uptake independent of insulin, promotes fatty acid oxidation, and improves exercise capacity. In mouse studies, MOTS-c administration reversed age-related metabolic decline and improved physical performance in old animals to near-youthful levels. NMN (Nicotinamide Mononucleotide) is a direct precursor to NAD+, the essential coenzyme for mitochondrial function, DNA repair (via sirtuins and PARPs), and hundreds of metabolic reactions. NAD+ levels decline approximately 50% between ages 40-60, contributing to mitochondrial dysfunction, impaired DNA repair, and metabolic dysregulation. While NMN is technically a supplement rather than a peptide, its inclusion in this stack reflects the reality that mitochondrial restoration requires adequate NAD+ substrate alongside structural (SS-31) and signaling (MOTS-c) interventions. This is an experimental cutting-edge protocol targeting the fundamental bioenergetic decline of aging.
Protocolo de Dosis
40,000 mcg
por dosis
10,000 mcg
por dosis
500,000 mcg
por dosis
Objetivos & Evidencia
Advertencias
- SS-31 completed Phase 3 for Barth syndrome. MOTS-c has limited human data. NMN is a supplement (not a peptide). This is an experimental combination.
Comments
Sign in to join the discussion
Aviso: Este stack es subido por la comunidad y solo tiene fines de investigación. Peptide Contacts no verifica la seguridad o eficacia de los stacks subidos. Siempre consulte a un profesional de la salud calificado antes de usar cualquier protocolo de péptidos.